Virginia Commonwealth University School of Medicine

Richmond, Virginia
Professor and Chairman, VCU Department of Human and Molecular Genetics
Director, VCU Institute of Molecular Medicine
Thelma Newmeyer Corman Chair of Cancer Research, VCU Massey Cancer Center


Dr. Fisher’s cancer research focuses on the daunting challenge facing clinicians and cancer patients, namely identifying, treating and monitoring cancers once they have metastasized from the primary tumor. His efforts have led to development of novel technologies that simultaneously detect and diagnose tumors as well as effectively treat them – or a theranostic approach. With NFCR funding since 2008, Dr. Fisher is now developing an immunotheranostic by genetically engineering a tumor suppressor previously discovered by him to produce a fluorescent (light) signal, allowing for diagnosis, treatment and monitoring of tumors. The fluorescent signal can be imaged using current non-invasive imaging techniques to detect the precise location of metastatic cells and monitor the tumor size after treatment.

NFCR funding has allowed Dr. Fisher to successfully incorporate the tumor suppressing immuno-theranostic into an ‘adoptive cell therapy’ to reduce prostate tumors in mice. In the laboratory, his adoptive therapy first collects the immune T cells from mice to genetically modify the cells with anticancer genes he discovered. After reinjection, the supercharged T cells seek out and deliver an immune enhancer gene that kills any prostate cancer cells. His therapy also provides an imaging tool to identify all metastases and monitor destruction of the tumor using non-invasive imaging. Dr. Fisher’s immuno-theranostic therapy could effectively treat not only metastatic prostate cancer but has the potential to treat virtually any solid tumor, and with modifications, blood cancers.


Paul Fisher, M.Ph., Ph.D., received his Bachelor’s degree from Hunter College and his Master’s from Lehman College. He went on to get his M.Ph. (Master of Public Health) and Ph.D. from Rutgers University, where he was also a postdoctoral fellow. Dr. Fisher later conducted research at Albert Einstein College of Medicine and at Columbia University, where he became a Professor of Clinical Pathology, the Director of Neuro-Oncology Research and the Michael and Stella Chernow Urological Cancer Research Scientist.

Dr. Fisher joined the faculty of the Virginia Commonwealth University’s (VCU) School of Medicine in 2008 and is currently a Professor and Chairman in the Department of Human and Molecular Genetics, Director of the VCU Institute of Molecular Medicine and holds the Thelma Newmeyer Corman Chair of Cancer Research in the VCU Massey Cancer Center.

In addition to his NFCR award, Dr. Fisher is a visiting research professor, eminent research scholar and adjunct professor at New York University, and a visiting professor at Burnham Institute for Medical Research. Dr. Fisher won the CaP CURE Award for Prostate Cancer Research in 1995 and the Lustgarten Award in 2003, 2004 and 2005. More recently, Governor Terry McAuliffe recognized Dr. Fisher as Virginia’s Outstanding Scientist of 2014.  Dr. Fisher is an elected member of the National Academy of Inventors. He has more than 55 issued U.S. patents and multiple foreign patents. In 2018, Dr. Fisher was invited to join the new, illustrious editorial board of the Journal of the National Cancer Institute (JNCI) and JNCI Spectrum.

Related Content

Research Highlight: Preventing Breast Cancer Brain Metastasis

National Foundation for Cancer Research funded researcher Dr. Daniel A Haber recently unearthed an exciting discovery that may add years to the lives of late-stage breast cancer patients. Dr. Haber is fascinated by understanding drug resistance on a deeper level by studying individual tumor cells in patients’ blood. In December 2020, Dr. Haber and his team shared their exciting findings on how brain metastasis, or the spread of cancer to the brain, may be prevented. Brain metastases occur in about 10% of all patients with cancer and in as many as a third of women with advanced metastatic breast cancer. Though experts have made great strides in suppressing the spread of cancer, there is still little known about the cellular pathways that enable cancer cells to selectively grow in the brain; that is, until Dr. Haber and his research team identified a signaling pathway which appeared significantly more active in brain metastases from breast cancer. “We were looking for what properties of some breast cancer cells made it possible for the cells to grow in the brain, which is a rare but often deadly complication of breast cancer,” Dr. Haber explained. “We weren’t sure what we would find. In a way that’s what makes the discovery process so exciting.” The research commenced approximately 10 years ago while investigating circulating tumor cells (CTCs). As their research progressed, the team homed in on a specific signaling pathway named HIF1A. Using cells from women with breast cancer, the team observed how these cells acted in animal models. It was discovered that if HIF1A was suppressed, the rate of proliferation (or rapid growth) was reduced. Simply put, blocking the HIF1A signaling pathway could reduce the rate of brain metastasis or even prevent it all together. “HIF1A is not specific to brain metastasis, since it’s a very broadly activated pathway in many cancers,” Dr. Haber began. “However, it appears to be more active in brain metastases from breast cancer than in primary breast cancers, and that may help explain what makes these metastases to the brain so unique and so difficult to treat.” The pathway identified in this research is already well known in the cancer world, however its special relevance to the brain was not known until now. Theoretically, a drug could be developed to suppress HIF1A and, in turn, prevent the spread of cancer. While a very promising discovery, Dr. Haber explains that there is far more work to be done. “There are a few HIF1A suppressing drugs now being tested in clinical trials for other indications,” Dr. Haber said, “However, we would have to expand this to multiple different models and systems before we could contemplate an intervention.” In regard to the length of time it takes to have a discovery such as this transitioned to mainstream treatment, Dr. Haber explains that it “depends on the discovery, its potential applications and some ‘luck’.” While the process from discovery to clinical treatment is getting faster all the time, it is likely going to take five to ten years before this finding is implemented into treatment. As for Dr. Haber, he has already planned plenty of work […]

3 Important Tips For Immuno-Oncology Drug Treatment

Immuno-oncology (IO) drugs have demonstrated unprecedented benefits in the treatment of several types of cancer. The overall survival time of cancer patients treated by IO drugs have been dramatically extended, and in some cases, even late stage fatal cancers are brought into remission by the IO-based immunotherapy. IO drugs work in a very unique way. Unlike the chemotherapy or targeted therapy drugs, IO drugs don’t target and kill cancer cells directly. Instead, they interact with the T-cells in patient’s immune system to help release more cancer-fighting power. For example, the most widely used IO drugs Nivolumab and pembrolizumab are PD-1 Immune Checkpoint Inhibitors (ICIs). Their function is to unlock the power of T-cells, the “soldiers” of the immune system, by taking off the “brake” function of immune “checkpoint” formed by the PD-1 molecules that prevent T-cells from attacking the cancer cells in patients. IO drugs are actually effective for all types of cancer as the drugs target patients’ immune system, which is unrelated to the types of cancer patients have. This uniqueness allows ICIs to be used to treat many types of late stage cancers, including metastatic skin cancer (melanoma) and the cancers in lung, breast, bladder, kidney and head and neck. None of the conventional therapies, such as chemotherapy and radiation therapy, have showed such level of dramatic therapeutic outcomes before. However, ICIs drugs are not perfect: they don’t work for everyone. The overall response rates to ICIs are only 15-20%, which means the majority of the patients won’t be able to get their therapeutic benefits. Information about which patients might benefit from which drugs is critical for doctors, but no conclusive data is available so far. By analyzing results from multiple separate retrospective studies, researchers at different institutions found out that Tumor Mutational Burden (TMB) might be a useful biomarker for doctors to predict whether a patient would respond to and get the benefits of ICIs treatment. TMB is one of the data obtained from a genetic testing Whole-Exome Sequencing that measures the total number of disease-relevant gene mutations within a particular region of DNA in patients with solid tumors. A high TMB Score indicates that the patient’s cancer cells might have enough targets for the T-cells to destroy them. This gives the doctors a practical clinical tool to identify the patients who are more likely to get the benefits from the ICIs treatment. Tip to Patients #1: ask your doctor if you are eligible to have the TMB test. If you have already done the test, ask if your TMB score is high enough to receive the ICIs treatment. The TMB-based assessment has been very helpful for doctors to make treatment decisions, but the final TMB score will be influenced by a variety of factors, such as sample quality and quantity, method of data analysis and the format of reporting. Standardization of testing and reporting procedures is the key to obtain a correct TMB score that enables doctors to make the right treatment decision. But doctors working at different hospitals may receive the TMB test results from different laboratories with different reporting formats, which make it very […]

Cancer Research Applied to Develop COVID-19 Treatment Strategies

New publication by NFCR-supported scientist Rakesh Jain, Ph.D., applies cancer research findings to help COVID-19 treatment in different patient groups. Few drugs for COVID-19 appear to work well in unselected patients, but now a new mathematical model provides insight into which patients benefit from which treatments. Researchers and investigators, including NFCR-funded Dr. Rakesh Jain, the principal investigator, from Massachusetts General Hospital, Brigham and Women’s Hospital and the University of Cyprus, have together published a new study in Proceedings of the National Academy of Sciences. This study uses a biology-based mathematical model, originally designed to make treatment decisions for cancer patients based on the conditions of inflammation and the immune system, to make the COVID-19 treatment more effective. The model has incorporated the disease and treatment information about SARS-CoV-2 (the virus that causes COVID-19), which allows the researcher to better understand and treat COVID-19. Jain and the team discovered that although the level of SARS-CoV-2 increases during the early stages of lung infection, it changes to different directions on day 5, depending on patient’s immune response, especially the level of recruited T-cells, the key and first responders of the immune system.   For healthy patients under 35 years old with sustained T-cell recruitment, if the viral level, inflammation and non-specific immune cells are all reduced, they usually have a lower risk of blood clot, their oxygen levels in the lung would be restored and this group of patients tend to recover well.  On the flip side, for older patients and those with pre-existing conditions such as diabetes, obesity, or high blood pressure, if they already have high levels of inflammation or non-specific immune cells, their treatment outcomes would be poor. These findings have led to the important treatment recommendations.  For older patients with existing inflammation, the sequence of treatment should be using the clot-preventing drug heparin and/or immunotherapy drugs (such as checkpoint inhibitors) in the early stages of the infection and the anti-inflammatory drug, such as dexamethasone, in later stages. For patients with pre-existing conditions or immune deficiency, treatment may include drugs that inhibit inflammation-promoting cytokines.  In addition, high blood pressure drugs that inhibit the renin-angiotensin system are recommended for preventing resistance to blood flow that may be caused by the viral infection. This impressive study displays how research originally developed for cancer treatment can be useful in combatting COVID-19, which poses a major risk to cancer patients. The National Foundation for Cancer Research is proud to support this collaborative research for the benefit of both cancer and COVID-19 patients. Learn more about the work of NFCR-supported researchers and scientists here and visit our COVID-19 Resource Center to stay up-to-date with the latest information on the coronavirus and cancer. Additional Reads You May Enjoy: New Discovery May Significantly Broaden the Applicability of T-Cell Immunotherapy Deadly Decisions: COVID-19 or CANCER? Stay connected with us! Receive our monthly e-newsletter and blogs featuring stories of inspiration, support resources, cancer prevention tips and more. Sign up here.